Use of GLP-1 RAs Associated With Increased Risk of NAION in Patients With Diabetes
Written by
American Journal Managed Care
Published
0
comments
0
min
Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).